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ABSTRACT 
Persistence of minimal residual disease (MRD) after treatment for myeloma predicts 
inferior outcomes, but within MRD-positive patients there is great heterogeneity with 
both early and very late relapses. Amongst different MRD techniques, flow cytometry 
provides additional information about antigen expression on tumor cells, which could 
potentially contribute to stratify MRD-positive patients. We investigated the prognostic 
value of those antigens required to monitor MRD in 1,265 newly-diagnosed patients 
enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and 
GEM2010MAS65 protocols. Overall, CD19pos, CD27neg, CD38lo, CD45pos, CD81pos, 
CD117neg and CD138lo expression predicted inferior outcomes. Through principal-
component-analysis, we found that simultaneous CD38lowCD81posCD117neg expression 
emerged as the most powerful combination with independent prognostic value for 
progression-free survival (HR:1.69; P =.002). This unique phenotypic profile retained 
prognostic value among MRD-positive patients. We then used next-generation flow to 
determine antigen stability throughout the course of the disease, and found that the 
expression of antigens required to monitor MRD is mostly stable from diagnosis to 
MRD stages, except for CD81 whose expression progressively increased from baseline 
to chemoresistant tumor cells (14% vs 28%). Altogether, we showed that the 
phenotypic profile of tumor cells provides additional prognostic information, and could 
be used to further predict risk of relapse among MRD-positive patients. 
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INTRODUCTION 
 In the past 15 years, treatment of multiple myeloma (MM) has improved 
dramatically due to progressively greater availability of active new drugs.(1–7) 
Accordingly, better techniques and biomarkers are needed to monitor treatment 
efficacy and predict outcome, in order to individualize therapy and avoid both under- 
and over-treating patients. Minimal residual disease (MRD) is emerging as an attractive 
biomarker to evaluate treatment efficacy and eventually, act as surrogate for superior 
outcomes based on significantly different MRD-negative rates.(8–10) Accordingly, the 
International Myeloma Working Group (IMWG) has recently reported new guidelines on 
response assessment that include criteria for MRD-negativity defined by next-
generation sequencing (NGS) and flow cytometry (NGF), and has recommended their 
inclusion in clinical trials.(11) Both molecular (12) and immunophenotypic (13) 
techniques used to monitor MRD have recently benefited from methodological 
optimization leading to improved sensitivity (up to 10-6), and better definition of MRD-
negative patients with significantly lower probability of relapse. Conversely, the ability 
to detect ultra-low levels of MRD is increasing the percentage of MRD-positive patients 
which, due to a plethora of other clinical and biologic features, will include cases with 
shorter vs remarkably longer progression-free (PFS) and overall survival 
(OS).(10,14,15) Thus, improved risk stratification of MRD-positive patients emerges as 
un unmet area of research that could provide additional information to help tailoring 
subsequent treatment and monitoring. 
 One of the advantages of NGF is to afford real-time information on other 
parameters beyond MRD, due to both the need to perform the assay on fresh samples 
and the ubiquitous expression on other cells of those antigens required to detect MRD. 
This unique feature of NGF has recently shown to be useful to assess quality of bone 
marrow (BM) aspirates and exclude hemodiluted samples (13), define patient-specific 
immune signatures associated with different outcomes (15), and provide insight into the 
biology of ultra-chemoresistant MRD cells.(16,17) More recently, we have identified 
new patterns of antigen expression based on CD19 and CD81 that defined normal and 
tumor plasma cells (PCs) with distinct levels of differentiation, and helped revealing 
through longitudinal comparison of diagnostic vs. MRD samples, that in a subset of 
patients, less-differentiated PCs subclones become enriched after therapy-induced 
pressure.(18) Thus, it could be hypothesized that the phenotypic profile of clonal PCs 
assessed either at diagnosis or during MRD stages could also afford valuable 
information, particularly if we could demonstrate that those antigens required to monitor 
MRD remain stable throughout the course of disease, and therefore are hallmarks of 
residual PC clones. Unfortunately, there is limited data on the prognostic value of 
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antigen expression after the incorporation of proteasome inhibitors (PIs) and immune 
modulators (IMIDs) in MM (18–20), and almost no information on the stability of those 
antigens from diagnosis to MRD stages.(16,18) 
 Here, we started by investigating in a very large series of 1,265 newly-
diagnosed MM patients enrolled into four consecutive PETHEMA/GEM protocols 
conducted before and after the incorporation of PIs and IMIDs, as well as in the 
transplant-eligible and -ineligible settings, the prognostic value of antigen expression at 
diagnosis. Afterward, we used NGF to compare in a cohort of 25 uniformly treated 
MRD-positive MM patients, the phenotypic profile of clonal PCs at diagnosis and MRD 
assessments after induction, intensification and consolidation. Overall, we defined a 
unique phenotypic profile with independent prognostic value, and that is rather stable 
from diagnosis to MRD stages. Accordingly, antigen expression of clonal PCs provides 
additional prognostic information that might potentially be used to further predict short 
vs long-term risk of relapse among MRD-positive patients. 
 
 
 
PATIENTS AND METHODS 
Patients and study designs. A total of 1,265 newly-diagnosed MM patients enrolled in 
four consecutive PETHEMA/GEM clinical trials (GEM2000 and GEM2005MENOS65 
for transplant-eligible; GEM2005MAS65 and GEM2010MAS65 for elderly patients), and 
with available immunophenotypic data at diagnosis to investigate the prognostic value 
of antigen expression were included in this study. The design of the GEM2000 
(NCT00560053) (21), GEM2005MENOS65 (NCT00461747) (22), GEM2005MAS65 
(NCT00443235) (23) and GEM2010MAS65 (NCT01237249) (24) protocols has been 
described elsewhere. Because in most cases diagnostic and MRD studies were both 
performed with 4-color immunophenotyping, we took advantage of the prospective 
incorporation of 8-color NGF in the GEM2012MENOS65 clinical trial to investigate 
whether the phenotypic profile of clonal PCs at MRD assessment stages reflects that 
found at diagnosis (n=25), or shows significant therapy-induced modulation of antigens 
required to monitor MRD. According to the design of the GEM2012MENOS65 protocol 
(NCT01916252), MRD was assessed in all patients after six induction cycles with 
bortezomib, lenalidomide and dexamethasone (VRD) followed by high-dose therapy 
(HDT) with melphalan or melphalan plus busulfan and autologous stem cell 
transplantation (ASCT), and two courses of consolidation with VRD (NCT01916252). 
We randomly selected 25 patients with persistent MRD at all time-points to compare 
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the phenotypic profile of clonal PCs at diagnosis vs MRD after various stages of 
treatment. Baseline demographics and patient characteristics per clinical trial are 
provided in Table 1. All samples were collected after informed consent was given by 
each patient, according to the local ethical committees and the Helsinki Declaration. 
Median follow-up of the whole series was of 69 months. 
 
Multiparameter flow cytometry. Erythrocyte-lysed whole BM samples from patients 
treated according to the GEM2000 protocol (n=479) were stained using a four-color 
direct immunofluorescence technique and the following monoclonal antibody (MoAb) 
[fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein-
cyanine 5.5 (PerCP-Cy5.5), allophycocyanine (APC)] combinations were used to 
identify aberrant antigen expression in PCs: i) CD38, CD56, CD19, CD45; ii) CD138, 
CD28, CD33, CD38; and iii) CD20, CD117, CD138, CD38.(25) Conversely, patients 
included in the GEM2005MENOS65 (n=316) and GEM2005MAS65 (n=238) studies 
were stained with following MoAb combinations (FITC, PE, PerCP-Cy5.5, APC): i) 
CD38, CD56, CD19, CD45; ii) CD38, CD27, CD45, CD28; and iii) β2microglobulin, 
CD81, CD38, CD117.(20) Acquisition was performed in a FACSCalibur™ flow 
cytometer (BD Biosciences [BD], San Jose, CA) using the CellQUEST program (BD), 
and information was recorded for 3x103 BMPC per combination. Regarding those 
patients enrolled in the GEM2010MAS65 clinical trial (n=232), approximately 200μL of 
EDTA-anticoagulated BM aspirated samples were immunophenotyped using two 
different 8-color combinations of MoAb - [Pacific Blue, Pacific Orange, FITC, PE, 
PerCP-Cy5.5, PE-cyanine 7 (PE-Cy7), APC, APCH7]: i) CD45, CD138, CD38, CD56, 
β2microglobulin, CD19, cyKappa, cyLambda; ii) CD45, CD138, CD38, CD28, CD27, 
CD19, CD117, CD81 – following the EuroFlow guidelines and the source of antibodies 
to identify clonal PCs, and characterize their phenotypic profile.(26) Data acquisition 
was performed for approximately 106 leukocytes/tube in a FACSCantoII flow cytometer 
(BD, San Jose, CA) using the FACSDiva 6.1 software (BD). Data analysis was 
performed using the Infinicyt software (Cytognos SL, Salamanca, Spain). 
 
Next-generation flow cytometry. We used NGF for real-time and sensitive MRD 
monitoring of patients enrolled in the GEM2012MENOS65 study (n=25). Briefly, the 
method is based on a (standardized) lyse-wash-and-stain sample preparation protocol 
that allows the measurement of high numbers of bone marrow (BM) cells (2x ≥5x106 
cells/tube), and an optimized 8-color, 2-tubes, antibody panel, for accurate 
identification of BM PCs and discrimination between phenotypically aberrant and 
normal PCs: tube 1: CD138-BV421, CD27-BV510, CD38-FITC, CD56-PE, CD45-
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PerCPCy5.5, CD19-PECy7, CD117-APC, CD81-APCH7 and; tube 2: CD138-BV421, 
CD27-BV510, CD38-FITC, CD56-PE, CD45-PerCPCy5.5, CD19-PECy7, cyKAPPA-
APC, cyLAMBDA-APCH7. The two-tube strategy allows detection of MRD with specific 
confirmation of monoclonality (through light-chain restriction) on phenotypically 
aberrant PCs, identified either by antigen under-expression (CD19, CD27, CD38, 
CD45, CD81) or antigen over-expression (CD56, CD117, CD138). Based on optimal 
source of antibodies, novel software tools for automatic PC gating and fusion of data 
corresponding to the two different aliquots/tubes described above using the Infinicyt ™ 
software (Cytognos, Spain) (13), the median limit of MRD detection was of 2x10-6. 
 
Fluorescence in Situ Hybridization (FISH) studies. Interphase FISH was performed 
on immunomagnetic-enriched PC at diagnosis (n=777). Patients were tested for 
t(4;14), t(14;16) and del(17p), amongst others. Those cases displaying any of the 
above were classified as having high-risk FISH, whereas all the others as standard-risk 
patients. 
 
Statistical analysis. PFS was measured from time of diagnosis to progression or 
death from any cause. OS was defined as time from diagnosis to death from any 
cause. Survival was analyzed by the Kaplan–Meier method, and differences between 
curves were tested for statistical significance with the (two-sided) log-rank test. A 
univariate analysis was conducted to assess the impact on PFS and OS of transplant-
eligibility, as well as various baseline prognostic factors including, the International 
Staging System (ISS), serum LDH levels, and FISH cytogenetics. A multivariate Cox 
proportional hazard model was developed to explore the independent effect on PFS 
and OS of variables with significant impact on the univariate analysis. Multivariate 
analysis and visualization of phenotypic and cytogenetic profiles was performed based 
on antigen expression profiles scaled from 0 to 100, using the t-SNE algorithm 
implemented in the Infinicyt software. For longitudinal analysis and comparison of 
quantitative and qualitative parameters related to the phenotypic profile of clonal PCs 
at diagnosis and at different MRD time-points, the Friedman and ANOVA tests for 
repeated measures with the Greenhause-Geisser correction factor were used, 
respectively. A P value <.05 was considered statistically significant. The SPSS 
software (version 20.0; IBM, Chicago, IL, USA) and the R environment software 
(version 3.2.3, The R Foundation for Statistical Computing) were used for statistical 
analyses. 
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RESULTS 
Prognostic value of antigen expression in multiple myeloma. We first investigated 
the prognostic value of those antigens required to monitor MRD in a large series of 
1,265 newly-diagnosed patients enrolled in the GEM2000 and GEM2005MENOS65 
protocols for transplant-eligible, and the GEM2005MAS65 and GEM2010MAS65 
protocols for elderly MM. Patients were dichotomized based on the percentage of 
clonal PCs expressing markers with bimodal patterns of expression (i.e.: CD19, CD27, 
CD45, CD56, CD81 and CD117), or based on the mean fluorescence intensity (MFI) in 
clonal PCs vs other nucleated cells of markers with unimodal patterns of expression 
(i.e.: low vs bright staining of CD38 and CD138). For the former set of markers, optimal 
expression cut-offs were defined based on the closest percent quartile to which the 
lowest P -value was reached for PFS (i.e.: 0%, 25%, 50%, 75% or 100% of clonal PCs 
expressing the marker). Pooled analysis of the 1,265 patients under study showed 
prognostic value for all markers analyzed except CD56 (Table 2). However, detailed 
analyses according to the type of treatment revealed that the negative impact of CD19 
(when positive in ≥50% clonal PCs) and, particularly, CD45 expression (when positive 
in ≥25% clonal PCs) was only significant in elderly patients (median PFS of 22 vs 32 
months, P =.001; median OS of 43 vs 60 months; P =.016). Conversely, the favorable 
effect of CD117 expression (when positive in ≥50% clonal PCs) was only significant in 
transplant-eligible patients treated without PIs and/or IMIDs (median PFS of 44 vs 32 
months, P =.004; median OS of 88 vs 52 months; P <.001). In turn, the patterns of 
expression of CD38, CD81 and CD138 were of prognostic value in all therapeutic 
protocols these markers were analyzed (Table 2). Patients with aberrantly low CD38 
MFI had inferior PFS (median of 30 vs 38 months; P <.001) and OS (median of 58 vs 
77 months; P <.001) vs cases with bright CD38 staining; comparable results were 
observed in patients with aberrantly low CD138 expression (median PFS of 29 vs 34 
months, P =.003; median OS of 55 vs 67 months, P =.04) compared to cases with 
bright CD138 staining. In turn, presence of ≥25% CD81+ve clonal PCs identified a 
subset of patients with inferior PFS (median of 24 vs 38 months; P <.001) and OS 
(median of 53 vs 81 months; P <.001). These results showed that most markers 
required to monitor MRD are of prognostic relevance in MM, but also that treatment 
intensification together with the use of more effective drugs, may modulate the 
prognostic impact of selected antigens. 
 
Defining a phenotypic profile to predict outcomes at diagnosis and MRD stages. 
Since many of the markers that are used to monitor MRD showed prognostic value, we 
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then used principal component analysis (PCA) to test all possible antigen combinations 
and unbiasedly define the overall phenotypic profile related with the greatest difference 
in patients’ survival. Thus, aberrantly low expression of CD38 together with reactivity 
for CD81 (≥25% positive PCs) in the absence of homogeneous expression of CD117 
(<50% positive PCs) identified a subset of patients (n=100; 9%) that compared to the 
remaining cases, had a significantly inferior PFS (median of 22 vs 35 months; P <.001) 
and OS (median of 43 vs 76 months; P <.001) (Figure 1A-B). The 
CD38lowCD81+CD117- phenotypic profile was also related to significantly higher rates of 
early relapse (i.e.: ≤12 months after diagnosis) as compared to the rest of cases (28% 
vs 17%; P =.011). Multivariate analysis of baseline prognostic factors for survival, 
including the phenotypic profile of clonal PCs plus patients’ eligibility for HDT/ASCT, 
ISS, LDH and FISH cytogenetics, together with patients’ MRD status after treatment, 
showed that the CD38lowCD81+CD117- phenotypic profile had an independent adverse 
effect in patients’ PFS (hazard ratio -HR-: 1.69; P =.002) as well as a trend for OS (HR: 
1.46; P =.093) (Table 3). Of note, despite significant associations were found between 
the expression of individual antigens and the presence of individual cytogenetic 
abnormalities (Supplementary Table 1), tSNE projection of the global phenotypic 
profiles of clonal PCs revealed that patients with high-risk FISH abnormalities – e.g.: 
t(4;14), t(14;16), and/or del(17p) - do not clustered together (Figure 2). Thus, patients 
with the adverse phenotypic profile defined above did not show a significantly higher 
frequency of high-risk FISH abnormalities vs all other cases (20% vs 19%; P =.5). 
Lastly, we investigated whether the CD38lowCD81+CD117- adverse phenotypic profile 
was also observed among patients with persistent MRD after treatment (n=396). As 
compared to all other MRD-positive patients, those cases displaying the 
CD38lowCD81+CD117- adverse phenotypic profile (n=45; 11%) had significantly shorter 
PFS (median of 24 vs 36 months; P =.002) and a trend towards inferior OS (median of 
53 vs 74 months; P =.058) (Figure 1C-D). Of note, MRD levels were not significantly 
different between MRD-positive patients displaying the CD38lowCD81+CD117- adverse 
phenotypic profile vs all other cases (median of 0.22% vs 0.11%; P =.67). 
 
Longitudinal comparison of phenotypic profiles of tumor plasma cells from 
diagnosis to MRD stages. Currently, data about antigen stability from diagnosis to 
MRD stages in MM is very limited, which prompted us to compare the antigen 
expression profile of clonal PCs at diagnosis and after various stages of therapy in a 
cohort of 25 MRD-positive patients homogenously treated according to the 
GEM2012MENOS65 protocol, and investigate whether the phenotypic profile of MRD 
clonal PCs after therapy represents that found at the time of diagnosis. In such case, 
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the presence of the unique phenotypic profile here identified, at diagnosis, would 
predict for more resistant MRD clones and adverse prognosis. As expected, tumor 
burden significantly decreased from diagnosis to MRD assessments after six cycles of 
induction with VRD, HDT/ASCT and two courses of VRD consolidation (median 
percentage of clonal PCs of 6%, 0.05%, 0.009% and 0.003%, respectively; P <.001) 
(Figure 3A). Thus, therapy-induced pressure over total clonal PCs at diagnosis led to 
the selection and persistence of very small numbers of chemoresistant MRD clonal 
PCs that, compared to patient-paired diagnostic PC clones, showed progressively 
higher expression of CD81 (mean percentage of positive clonal PCs at diagnosis, after 
induction, HDT/ASCT and consolidation of 14%, 15%, 22% and 28%; P =.002). In 
contrast, no significant differences were noted on the levels of expression of CD38 and 
CD138, nor the percentage of clonal PCs expressing CD19, CD27, CD45, CD56 and 
CD117 (Figure 3B). Overall, shifts in antigen expression (i.e.: from negative to ≥20% of 
positive clonal PCs or vice-versa) for any of the six markers under study which showed 
bimodal expression were observed in only 13 out of the 75 (17%) MRD BM samples 
analyzed (e.g. in a patient with double-antigen shift illustrated in Figure 3C). Thus, 
these results indicate that the overall phenotypic profile of clonal PCs from MM patients 
at diagnosis remains largely stable at different MRD stages, and that the potential 
prognostic value of antigen expression assessed after treatment in chemoresistant 
cells could be inferred from that found at diagnosis (Supplementary Figure 1). 
 
 
DISCUSSION 
 The relevance of MRD monitoring in MM has significantly increased in recent 
years, evolving from a biomarker used to assess tumor contamination of stem cell 
harvests into one of the best predictors of outcome and, eventually, a surrogate of PFS 
and OS.(27) In parallel, traditional immunophenotypic and molecular methods have 
been replaced by more sensitive next-generation techniques, recently adopted by the 
IMWG to define NGF- and NGS-based MRD negative criteria.(11) Here, we 
investigated the prognostic value of those immunophenotypic markers required to 
monitor MRD by flow cytometry in one of the largest series of newly-diagnosed MM 
patients enrolled into four consecutive Spanish protocols; simultaneous expression of a 
CD38lowCD81+CD117- phenotypic profile was identified as the most powerful 
combination to discriminate patients with inferior outcomes, and it provided additional 
information to stratify risk among patients with persistent MRD. 
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 In this study, we also provide novel and practical information for those using 
NGF to monitor MRD in MM. In acute myeloid leukemia, it is well-known that the 
immunophenotype of the leukemic clone may change between diagnosis and relapse 
due to subclonal selection/evolution, which has important consequences for MRD 
detection, due to potential false-negative results after disappearance of aberrant 
phenotypes used as MRD markers.(28) Here, we showed for the first time that, for 
different treatment stages, shifts in antigen expression during MRD assessment take 
place in a small subset of MM patient samples (17%), and mostly involving CD81. 
Thus, while information about the patients’ phenotype at diagnosis might be helpful to 
monitor MRD, it should not be misleading given the possibility of antigen instability from 
diagnosis to MRD stages in a few patients. However, changes in one particular antigen 
do not affect MRD detection in MM, which is based in the assessment of multiple 
phenotypic aberrancies that are detected by using multidimensional (≥8) and optimal 
combination of mAbs; in fact, it has been recently shown that it is possible to detect 
clonal PCs irrespectively of the patient-specific phenotypic aberrancies.(13) This allows 
the use of NGF-based MRD assessment, even in the absence of diagnostic samples, 
in virtually all MM patients.(13) Furthermore, the two-tube NGF approach also allows 
confirmation in a second independent measurement of the clonal nature of 
phenotypically aberrant PCs, through evaluation of cytoplasmic κ/λ immunoglobulin 
light-chain restriction.(13) Thereby, as shown here, the capability of detecting MRD 
remains identical in patients with or without antigen stability from diagnosis to different 
MRD stages.   
 Despite the use of highly effective drug combinations, next-generation MRD 
techniques have recently demonstrated that a great fraction of the patients still remains 
MRD positive after treatment.(12,13,29) Interestingly however, whereas with 
conventional therapies the prognosis of MRD-positive patients has been typically 
adverse (10,30,31), more recent studies, particularly those conducted after the 
incorporation of daratumumab revealed that the outcome of some MRD-positive 
patients can be remarkably improved.(32) Whenever such monoclonal antibody-based 
therapies will become a mainstay in the treatment of MM, it would thereby become 
important to identify other markers capable of discriminating among MRD-positive 
patients, those that may reach long-term survival vs those at risk of short-term 
progression. We and others had previously reported that the presence of high-risk 
cytogenetics at baseline identifies a subset of MRD positive patients with dismal 
survival (10,14,15,33); here, we describe that simultaneous to MRD assessment, NGF 
could also provide additional prognostic information based on the phenotypic profile of 
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clonal PCs; thus, patients displaying a CD38lowCD81+CD117- antigen expression profile 
would be at risk of significantly shorter survival. It should be noted that through t-SNE 
projection no clear correlation between the presence of high-risk cytogenetic 
abnormalities and such unique phenotypic profile was found; thus, information on the 
later would be complementary to improve risk stratification of MRD-positive patients.  
 One limitation of the present study was the usage of different monoclonal 
antibody conjugates from older into more recent clinical trials. However, it should be 
noted that either the percentage or MFI of marker expression on clonal PCs was 
compared vs other nucleated cells in each individual sample, and not longitudinal 
across trials. Because interpretation of marker expression is thus based on the sample 
internal controls (i.e.: other BM nucleated cells), it is possible to pool data from different 
clinical trials for comprehensive analyses about the prognostic value of antigen 
expression. The favorable prognosis of MM patients with CD117+ expression has been 
hypothesized due to an altered homing of clonal PCs in the BM towards neutrophil 
precursor niches, thereby contributing to a greater maintenance of residual normal 
PCs.(34) Taking advantage of the large series of patients included in this study treated 
according to four different treatment protocols, we observed that when analyzed 
individually, the pattern of CD117 expression loses prognostic significance after PIs 
and IMIDs have been introduced. These findings could be related to the ability of these 
drugs to disturb the tumor microenvironment. Most recently, we demonstrated that MM 
patients harboring less-differentiated PCs, defined in part by CD81+ expression, had 
dismal survival, could be related to the higher chemoresistant potential of less 
differentiated PC clones.(18) Here, we confirm previous observations about the 
prognostic role of CD81 in MM (18,20), and showed that similarly to what has been 
described in transplant-ineligible patients, less-differentiated PC subclones also 
become significantly enriched after HDT/ASCT. Furthermore, a CD38low CD45+ CD81+ 
phenotypic profile emerged as the most powerful to identify a small subset of patients 
(n=29, 2,3%) out of which almost half relapsed in the first 12 months after diagnosis 
(46% vs 18% in the rest of patients; P <.001). Based on recent data suggesting a 
potential role for the all-trans retinoic acid in improving the efficacy of daratumumab via 
up-regulation of CD38 expression (35), it might be worth to investigate whether drugs 
able to induce cellular differentiation could improve the outcome of patients with less-
differentiated CD81+ clonal PCs. Conversely, the phenotypic profile of MRD cells could 
also potentially contribute to optimize the use of specific immunotherapies targeting 
surface antigens. CD38 is a multifunctional cell surface glycoprotein that serves as 
both a receptor for the transduction of activation/proliferation signals and an 
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ectoenzyme that catalyzes the production of nucleotides involved in calcium 
signaling.(36) However, given the end-stage long-lived and quiescent phenotype of 
CD38bright PCs vs CD38low plasmablasts, it could be hypothesized that rather than 
signaling, CD38 acts as a marker of migration and adhesion properties involved in 
anchoring PCs to the BM stroma.(37,38) Interestingly, we and others have reported 
that like normal peripheral blood PCs, MM circulating tumor cells also show lower 
levels of surface CD38 and CD138 vs their BM clonal PCs counterpart.(39,40) Here, 
we confirm on preliminary data (41) indicating that MM patients with CD38low and 
CD138low expression have significantly inferior PFS and OS as compared to patients 
with normal (bright) CD38 levels. In fact, the CD138highCD38highCD19- phenotypic 
profile emerged as the most powerful combination to define a subset of patients 
(n=299; 34%) that compared to the rest of cases, displayed significantly superior PFS 
(median of 39 vs. 30 months; P <.001) and OS (median of 71 vs 59 months; P <.001). 
Furthermore, this phenotypic profile remained significant even MRD-positive patients; 
those cases displaying the CD138highCD38highCD19- phenotypic profile (n=90; 32%) 
had significantly longer PFS (median of 37 vs 32 months; P =.017) and OS (median of 
81 vs 65 months; P =.007). Since recent data obtained in a phase I study suggested 
that patients with lower CD38 expression showed a smaller benefit after treatment with 
daratumumab (42), further investigation in larger series of patients are warranted to 
understand if the use of different immunotherapy modalities can be tailored according 
to the density of antigen target molecules on the surface of clonal PCs.  
 Due to the progressively higher efficacy of novel drug combinations, there is 
risk for persistent MRD to be generally considered as a treatment failure, even though 
not all MRD-positive patients are at high-risk of progression and some may even reach 
long-term survival.(10) Overall, this study shows that phenotypic characterization of 
clonal PCs could be of added value to stratify risk among patients with persistent MRD 
by sensitive next-generation MRD techniques. Further studies based on modern 
treatment regimens and with a redefined MRD-positive patient population based on the 
higher sensitivity of NGF, are warranted to establish the role of phenotypic 
characterization of MRD clonal PCs. 
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Figure 1. Defining a phenotypic profile to predict outcomes. We used R 
environment to test all possible antigen combinations and define the phenotypic profile 
related with the greatest difference in patients’ survival. Accordingly, aberrantly low 
expression of CD38 together with reactivity for CD81 (≥25% positive PCs) in the 
absence of homogeneous expression of CD117 (<50% positive PCs) identified a 
subset of patients that compared to the rest of cases, had significantly inferior 
progression-free and overall survival both when analyzed in all patients (A-B) as well 
as in those with persistent MRD after treatment (n=396; C-D).  
 
Figure 2. Correlation between phenotypic and cytogenetic profiles. t-Distributed 
Stochastic Neighbor Embedding (t-SNE) projection of the patients’ phenotypic profiles 
defined by antigen expression in PCs at the time of diagnosis (n=672). Patients without 
any high-risk cytogenetic abnormality [i.e.: t(4;14), t(14;16) and/or del(17p)] are 
represented by grey circles (n=544), whereas patients with t(14;16) and del(17p) (n=2), 
t(4;14) and del(17p) (n=9), del(17p) (n=44), t(4;14) and t(14;16) (n=2), t(14;16) (n=9), 
and t(4;14) (n=61) are highlighted as in blue, pink, dark-green, red, light-green, and 
brown squares, respectively. 
 
Figure 3. Longitudinal analysis of phenotypic profiles on clonal plasma cell (PCs) 
analyzed at diagnosis vs MRD stages. (A) Percentage of bone marrow (BM) clonal 
PCs at diagnosis and during minimal residual disease (MRD) monitoring after 6 
induction cycles with bortezomib, lenalidomide, dexamethasone (VRD), high-dose 
therapy followed by autologous stem cell transplantation (HDT/ACST) and 2 courses of 
VRD consolidation, according to the GEM2012MENOS65 clinical trial (n=25).  Dots 
and vertical lines represent median values and 25th-75th percentiles, respectively. (B) 
Comparison of clonal PCs phenotypic profiles was performed in longitudinal samples 
available at all timepoints. Antigen expression is represented as the percentage of 
clonal PCs expressing the marker, or as mean fluorescence intensity (MFI) for markers 
with unimodal expression (i.e.: CD38 and CD138). Each dot represents an individual 
patient. (C) Bivariate dot-plots of a patient representative of shifts in antigen expression 
on clonal PCs from diagnosis to MRD stages (e.g.: CD81 and CD117). The percentage 
of BM clonal PCs in each timepoint is indicated between brackets. 
 
  
